AstraZeneca eyes rare endocrinology market with $1.05B buyout of Amolyt Pharma
AstraZeneca is bulking up its late-stage rare disease pipeline by acquiring Amolyt Pharma in a $1.05 billion deal, bringing in a drug for “one of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
